|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020852,
umls-concept:C0020971,
umls-concept:C0026724,
umls-concept:C0026809,
umls-concept:C0205263,
umls-concept:C0205373,
umls-concept:C0229671,
umls-concept:C0442711,
umls-concept:C0913822,
umls-concept:C0913823,
umls-concept:C1511253,
umls-concept:C2754992
|
|
pubmed:issue |
28-29
|
|
pubmed:dateCreated |
2001-6-27
|
|
pubmed:abstractText |
We tested the immunogenicity in mice of a recombinant fusion protein (gp41HA) consisting of the ectodomain of the HIV-1(IIIB) envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. An intraperitoneal prime followed by intranasal or intragastric boosts with gp41HA induced high concentrations of serum IgG antibodies and fecal IgA antibodies that reacted with gp41 in HIV-1(IIIB) viral lysate and were cross-reactive with gp41 in HIV-1(MN) lysate. By indirect immunofluorescence, serum IgG and fecal IgA from immunized mice were also shown to recognize gp41 in acetone-fixed human peripheral blood mononuclear cells infected with either syncytium-inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells. Thus, this recombinant antigen may be useful in prime/boost immunization protocols designed to induce systemic and mucosal antibodies that recognize multiple primary HIV-1 isolates.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3990-4001
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11427275-AIDS Vaccines,
pubmed-meshheading:11427275-Animals,
pubmed-meshheading:11427275-Antibody Specificity,
pubmed-meshheading:11427275-Female,
pubmed-meshheading:11427275-HIV Antibodies,
pubmed-meshheading:11427275-HIV Envelope Protein gp41,
pubmed-meshheading:11427275-HIV-1,
pubmed-meshheading:11427275-Hemagglutinin Glycoproteins, Influenza Virus,
pubmed-meshheading:11427275-Humans,
pubmed-meshheading:11427275-Immunity, Mucosal,
pubmed-meshheading:11427275-Immunization, Secondary,
pubmed-meshheading:11427275-Immunoglobulin A, Secretory,
pubmed-meshheading:11427275-Immunoglobulin G,
pubmed-meshheading:11427275-Mice,
pubmed-meshheading:11427275-Mice, Inbred BALB C,
pubmed-meshheading:11427275-Neutralization Tests,
pubmed-meshheading:11427275-Recombinant Fusion Proteins,
pubmed-meshheading:11427275-Vaccines, Synthetic
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies.
|
|
pubmed:affiliation |
GI Cell Biology Laboratory, Enders 1220, Children's Hospital, 300 Longwood Avenue, 02115, Boston, MA, USA
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
